# Eli Lilly's Weight-Loss Drug Shows Significant Results in Trials

Retatrutide demonstrates potent effects in diabetes and obesity patients.

- **Source:** [TIME](https://time.com/)
- **Published:** 2026-09-29
- **Original article:** <https://time.com/article/2026/09/29/eli-lilly-triple-targeting-experimental-weight-loss-drug-promising-results/>
- **On Brifing:** https://brifing.si/s/91891bfe-0835-46d4-8357-13b5d9718270

## Breakthrough in weight-loss treatment

Eli Lilly's experimental drug retatrutide showed significant weight loss in two separate studies. In one study involving overweight or obese individuals with Type 2 diabetes, participants lost up to 18.8% of their body weight. The drug proved more effective than existing medications, with about a third of participants losing at least 25% of their weight. These results were published in the Lancet and presented at the European Association for the Study of Diabetes.

## Dual benefits for diabetes patients

Beyond weight loss, retatrutide improved diabetes control in participants. 63% of those on the highest dose achieved an A1C level below 6.5%, the diabetes threshold, while also losing at least 10% of their body weight. This dual effect addresses two major health challenges simultaneously. The study's medical director noted this as the most potent pharmacological agent for weight loss in diabetic patients to date.

## Effective for non-diabetic obesity

A second study in the New England Journal of Medicine showed similar results in overweight individuals without diabetes. Participants lost about 25% of their starting weight, compared to just 3.9% in the placebo group. The drug also showed benefits for other conditions, with participants reporting reduced knee pain from osteoarthritis and fewer sleep apnea episodes. These findings expand the potential patient population for the treatment.

## Triple hormone mechanism

Retatrutide works by targeting three weight-related hormones: GLP-1, GIP, and glucagon. This triple action may explain its superior efficacy compared to existing drugs that target only GLP-1 (like Ozempic) or GLP-1 plus GIP (like Mounjaro). Each hormone has specific receptors in the body and brain, suggesting the comprehensive approach creates more potent metabolic effects. The mechanism represents a significant advancement in obesity treatment science.

## Comparison to existing treatments

Current GLP-1 drugs like Wegovy and Ozempic are approved for weight loss and heart disease risk reduction, while Zepbound treats both obesity and sleep apnea. Retatrutide's broader hormone targeting and superior weight loss percentages position it as a potential market leader. However, side effects were similar to existing medications, including gastrointestinal issues such as nausea and abdominal cramps.

## Regulatory timeline

Eli Lilly plans to submit retatrutide for FDA approval in early 2027 based on these study results. The 1.5-year study period provides substantial data on efficacy and safety. If approved, the drug could enter a rapidly growing obesity treatment market currently dominated by GLP-1 medications. The company's submission timing suggests potential commercial availability by late 2027 or early 2028.

## Market implications

The obesity drug market is projected to exceed $100 billion annually, with current treatments showing strong demand. Retatrutide's superior efficacy could capture significant market share from existing therapies. Its additional benefits for diabetes control and other conditions may justify premium pricing. The drug's success could also spur further research into multi-hormone targeting approaches for metabolic diseases.

## Future treatment landscape

Retatrutide's promising results suggest a new standard in obesity pharmacotherapy. Its triple-hormone approach may become the benchmark for future drug development. The significant weight loss percentages, especially in diabetic patients, address a critical unmet medical need. As obesity rates continue rising globally, such advancements could transform public health outcomes and reduce related comorbidities.

## Sources covering this story

- https://time.com/article/2026/09/29/eli-lilly-triple-targeting-experimental-weight-loss-drug-promising-results/ — 

---

_Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._